To study the effect of Coenzyme Q10 on Insulin Resistance in Polycystic ovary syndrome patients

A prospective randomized open label study to evaluate effect of Coenzyme Q10 as an add-on to standard treatment in Insulin Resistant Polycystic ovary syndrome - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/11/077101

Enrollment

Registered

2024-11-20

Start date

Unknown

Completion date

Unknown

Last updated

2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N914- Secondary oligomenorrhea

Interventions

Intervention1: Coenzyme Q 10: Cap.Coenzyme Q10 200mg once daily after breakfast - intervention Control Intervention1: placebo: matching placebo capsules - comparator

Eligibility

Inclusion criteria

Inclusion criteria: newly diagnosed PCOS as per modified rotterdam criteria

Exclusion criteria

Exclusion criteria: Pregnant and lactating women, Subjects with type 1 or 2 Diabetes, Subjects who are on Metformin and/or COC pills for past 3 months, Subjects with history of hypo/hyperthyroidism, 9. Any medical condition or comorbidities, which in the clinician opinion could affect the safety and wellbeing of subjects.

Design outcomes

Primary

Measure	Time frame
Change in HOMA-IR between the groupsTimepoint: 3 months	—

Secondary

Measure	Time frame
Change in FBS, PPBS, HbA1c between the groups, within the group; Change in MDA between the groups, within the group; Incidence of adverse events with the study drug Timepoint: 12 weeks	—

Countries

India

Contacts

Public ContactDr P Usha rani

Nizams Institute of Medical Sciences

ushapingali@yahoo.com984957414

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026